Results 211 to 220 of about 54,884 (249)

Adoptive T-cell therapy.

Seminars in hematology, 1999
Adoptive immunotherapy, or the transfer of immunocompetent cells, has been shown to be a promising new strategy for treatment of a variety of malignancies, including leukemia and non-Hodgkin's lymphoma. The possibility that it may likewise benefit patients with multiple myeloma is now being explored by researchers in Europe and the United States.
Lokhorst, H.M., Liebowitz, D.
openaire   +2 more sources

Adoptive T-Cell Therapy of Cancer

Hematology/Oncology Clinics of North America, 2006
Adoptive therapy involves the transfer of ex vivo expanded immune effector cells to patients as a means of augmenting the antitumor immune response. In general, this transfer is accomplished by harvesting cells from the peripheral blood, tumor sites, or draining lymph nodes and expanding effector cells in a specific or nonspecific fashion for adoptive ...
openaire   +2 more sources

Adoptive T-Cell Therapy in Sarcomas

Current Oncology Reports
To summarise and evaluate the latest adoptive T-cell therapies in sarcomas, focusing on therapeutic targets, efficacy, safety, and limitations.An increasing number of clinical trials are investigating adoptive T-cell therapies in sarcomas, most targeting NY-ESO-1 and MAGE-A4 through engineered T-cell receptors (TCR-T). The FDA approval of afamitresgene
Monika, Kucharczyk, Emine, Hatipoglu, Robin L, Jones, Paul H, Huang   +3 more
openaire   +2 more sources

Principles of adoptive T cell therapy in cancer

Seminars in Immunopathology, 2018
Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers.
Ozcan Met, Kasper Mølgaard Jensen, Inge Marie Svane   +2 more
exaly   +4 more sources

Adoptive T-Cell Therapy for Solid Malignancies

Surgical Oncology Clinics of North America, 2019
The use of immunotherapies for solid and hematologic malignancies has demonstrated durable antitumor effects. Use of checkpoint inhibitors allows for immunologic reactivation of the adaptive immune system against tumor-specific neoantigens and effective rejection.
Mohammad S, Jafferji, James C, Yang
openaire   +2 more sources

Neoantigen-Specific T Cells in Adoptive Cell Therapy

The Cancer Journal, 2022
Abstract The holy grail of cancer therapeutics is the destruction of cancer cells while avoiding harm to normal cells. Cancer is unique from normal tissues because of the presence of somatic mutations that accumulate during tumorigenesis.
openaire   +2 more sources

Adoptive T cell therapy of solid cancers

Cancer Immunology, Immunotherapy, 2005
The development of immune-based approaches for the treatment of cancer has been actively investigated for many years. One strategy that has emerged as a potentially effective strategy for the treatment of aggressive established malignancies is adoptive T cell therapy. The power of this approach has been repeatedly observed in preclinical animal models.
Keith L, Knutson, Wolfgang, Wagner, Mary L, Disis   +2 more
openaire   +2 more sources

T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy

Critical Reviews in Immunology, 2019
The past decade has seen enormous progress in cancer immunotherapy. Checkpoint inhibitors are a class of immunotherapy that act to recruit endogenous T cells of a patient's immune system against cancer-associated peptide- MHC antigens. In this process, mutated antigenic peptides referred to as neoantigens often serve as the target on cancer cells that ...
Preeti, Sharma, David M, Kranz
openaire   +2 more sources

Adoptive T cell therapy: points to consider

Current Opinion in Immunology, 2018
Adoptive Cell Therapy (ACT) has enjoyed a revival in recent years with the approval of CAR T cells for the treatment of patients with B cell malignancies. Advancing the use of adoptively transferred T cells for the treatment of patients with solid tumor and other hematologic malignancies however, will require addressing numerous effector cell intrinsic
openaire   +2 more sources

Exploiting Cytokines in Adoptive T-Cell Therapy of Cancer

Immunotherapy, 2015
Adoptive immunotherapy with tumor-reactive autologous T cells, either expanded from tumor specimens or genetically engineered to express tumor-reactive T-cell receptors and chimeric antigen receptors, is holding promising results in clinical trials. Several critical issues have been identified and results underline the possibility to exploit cytokines ...
Elisabetta Petrozziello, Tabea Sturmheit, Anna Mondino   +2 more
openaire   +2 more sources